On its 7th anniversary, Equilibria highlights its Continuous Care Model—supporting nearly 500,000 women through personalized cannabinoid protocols—as federal policy begins to recognize the role of plant-based therapeutics in modern care.
What the CMS Innovation Center Initiative Means for Cannabinoid Care
The recent CMS Innovation Center initiative introduces a pathway for participating providers to consult with patients about eligible hemp products within select value-based care models. While limited in scope, the move signals a broader shift: cannabinoids are beginning to be evaluated not as retail products, but as part of modern, outcomes-driven care delivery.
“For years, women have been using cannabinoids to manage sleep disruption,chronic stress, pain, and hormonal imbalance—largely without enough clinicalguidance,” said Coco Meers, Co-Founder and CEO of Equilibria.
“We built Equilibria on a simple belief: if this plant is going to be used as medicine, it needs to be supported like medicine. Today’s policy momentum suggests the system is starting to recognize that.”
How Equilibria's Continuous Care Model Has Supported Nearly 500,000 Women
Since its founding, Equilibria has supported nearly 500,000 women through personalized cannabinoid and functional wellness protocols.
Each member is paired with a trained Dosage Specialist and supported through hundreds of thousands of 1:1 care interactions across phone, chat, and email, including more than 67,000 live consultations. This model emphasizes careful titration, safety screening, education, and ongoing protocol refinement based on individual response.
The Clinical Standards Equilibria Believes Cannabinoid Care Requires
● Standardized dosing frameworks
● Guided patient education
● Screening for contraindications and polypharmacy risks
● Ongoing monitoring and adjustment over time
These principles are increasingly central to national policy discussions. As a founding member of the National Compassionate Care Council, Equilibria supports efforts to expand compassionate access, establish clinical standards, and generate real-world evidence through physician-guided care models.
Importantly, the CMS pathway does not create a broad Medicare benefit for cannabinoid products. Instead, it enables participating organizations to explore structured consultation and integration within defined care settings, with an emphasis on data collection, patient outcomes, and clinical oversight.
longitudinal care is essential.
“The companies that will define this category going forward are not just product companies,” Meers added. “They are care platforms—capable of supporting patients over time, generating real-world evidence, and integrating with the broader healthcare ecosystem. That’s what we’ve been building for the past seven years.”
About Equilibria
Equilibria is a women-founded wellness company delivering personalized
cannabinoid and functional wellness support designed for modern women. The company has helped nearly 500,000 women build sustainable routines for sleep,
stress, hormonal health, and overall resilience through expert guidance, ongoing
dosage support, and an education-first approach. Its Continuous Care model
combines premium formulations with individualized, longitudinal
support—positioning Equilibria at the forefront of a more structured,
patient-centered future for cannabinoid care.
